1. Enhanced anti-tumor effects of HPV16E7(49-57)-based vaccine by combined immunization with poly(I:C) and oxygen-regulated protein 150
- Author
-
Bing Ni, Rongying Ou, Jun Tang, Yuzhang Wu, Jennifer C. van Velkinburgh, Yunsheng Xu, Shisheng Chen, and Xiufang Deng
- Subjects
Cancer Research ,Epidemiology ,medicine.medical_treatment ,Papillomavirus E7 Proteins ,Uterine Cervical Neoplasms ,Lymphocyte proliferation ,Lymphocyte Activation ,Cancer Vaccines ,chemistry.chemical_compound ,Mice ,Immune system ,In vivo ,Interferon ,Heat shock protein ,medicine ,Cytotoxic T cell ,Animals ,Humans ,HSP70 Heat-Shock Proteins ,Vaccines, Combined ,Human papillomavirus 16 ,business.industry ,Papillomavirus Infections ,Vaccination ,Proteins ,Neoplasms, Experimental ,Molecular biology ,Xenograft Model Antitumor Assays ,Peptide Fragments ,Mice, Inbred C57BL ,Disease Models, Animal ,Poly I-C ,Oncology ,chemistry ,Polyinosinic:polycytidylic acid ,Cancer research ,Female ,business ,Adjuvant ,medicine.drug ,T-Lymphocytes, Cytotoxic - Abstract
Background : It is well known that both heat shock protein (HSP) and Toll-like receptor (TLR)3 agonist polyinosinic:polycytidylic acid (poly(I:C)) are capable of promoting the antigen-specific immune responses. In the current study, we assessed whether the anti-tumor effects of the HPV16E7 49–57 -based vaccine can be elevated by combined applications of poly(I:C) and oxygen-regulated protein 150 (ORP150) in a mouse cervical cancer model. Methods : Recombinant mouse ORP150 and HPV E7 49–57 peptide were combined to passively form the ORP150–E7 49–57 complex under heat shock conditions. The effects of ORP150–E7 49–57 complex plus poly(I:C) adjuvant on lymphocyte proliferation and functional cytotoxic T cells were investigated by methyl thiazolyl tetrazolium (MTT), ELISPOT, and non-radioactive cytotoxicity assays. Finally, the complex's therapeutic anti-tumor effects with and without adjuvant therapy were observed in a tumor challenge experiment. Results : This combination vaccine approach significantly enhanced the proliferation of splenocytes and induced strong E7 49–57 -specific CTL responses. More importantly, the ORP150–E7 49–57 complex plus poly(I:C) vaccine format demonstrated more potent anti-tumor effects than ORP150–E7 49–57 complex alone or E7 49–57 plus poly(I:C) in TC-1 tumor-bearing mice. Conclusion : Both poly(I:C) and ORP150 chaperone can synergistically enhance the anti-tumor effects of the HPV16E7 49–57 -based vaccine in vitro and in vivo. This strategy provides a platform for the design of a tumor therapeutic vaccine capable of inducing an effective anti-tumor immune response.
- Published
- 2012